EMA and European Organisation for Research and Treatment of Cancer (EORTC) workshop: How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions?, Online, European Medicines Agency, Amsterdam, t[...]

This workshop will bring together international experts from academia, learned societies, patients, regulatory agencies, health technology assessment bodies, and industry.

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/events/ema-european-organisation-research-treatment-cancer-eortc-workshop-how-can-patient-reported-outcomes-pro-health-related-quality-life-hrqol-data-inform-regulatory-de…https://www.ema.europa.eu/en/events/ema-european-organisation-research-treatment-cancer-eortc-workshop-how-can-patient-reported-outcomes-pro-health-related-quality-life-hrqol-data-inform-regulatory-de…
Retrieved on: 
Sunday, March 10, 2024
Information
Tags: 
Pros, EMA, PRO, Research, Facilitation, Quality of life (healthcare), Treatment, Location, European Medicines Agency, Patient, HRQOL, Medical device
Summary
Key Points: 
  • This workshop will bring together international experts from academia, learned societies, patients, regulatory agencies, health technology assessment bodies, and industry.
  • The aims of the workshop are to:
    - Understand the current global landscape on the use of PROs and HRQOL for evaluation of anti-cancer treatments across different stakeholder groups.
  • - Understand the use of validated PRO questionnaires to measure core HRQOL outcomes and disease-related symptoms; and PRO Item Libraries in the development of trial-specific/treatment-specific item lists.
  • The recording of this meeting will be made available after the event.
Copyright: 
2024 European Medicines Agency. All Rights Reserved.